Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma.
drug repositioning
drug repurposing
head and neck cancer
mepacrine
quinacrine
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
27 Aug 2019
27 Aug 2019
Historique:
received:
13
04
2019
accepted:
17
07
2019
entrez:
10
9
2019
pubmed:
10
9
2019
medline:
10
9
2019
Statut:
epublish
Résumé
Despite highly toxic treatments, head and neck squamous cell carcinoma (HNSCC) have poor outcomes. There is an unmet need for more effective, less toxic therapies. Repurposing of clinically-approved drugs, with known safety profiles, may provide a time- and cost-effective approach to address this need. We have developed the AcceleraTED platform to repurpose drugs for HNSCC treatment; using
Identifiants
pubmed: 31497252
doi: 10.18632/oncotarget.27156
pii: 27156
pmc: PMC6718257
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5229-5244Subventions
Organisme : Medical Research Council
ID : MR/M009157/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N023498/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST None.
Références
Oral Oncol. 2002 Oct;38(7):699-705
pubmed: 12167423
Hum Mutat. 2003 Aug;22(2):158-65
pubmed: 12872257
Cancer Res. 1955 Oct;15(9):573-8
pubmed: 13261076
Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
BMC Infect Dis. 2004 Nov 29;4:53
pubmed: 15569390
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6568-78
pubmed: 18006756
Methods Mol Biol. 2008;445:77-88
pubmed: 18425443
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Head Neck Oncol. 2009 Aug 13;1:32
pubmed: 19678942
Future Oncol. 2009 Dec;5(10):1685-704
pubmed: 20001804
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Cell Commun Signal. 2011 May 15;9:13
pubmed: 21569639
Science. 2011 Jun 24;332(6037):1492
pubmed: 21700846
Cancer Lett. 2012 Jan 28;314(2):232-43
pubmed: 22019047
Oncol Res. 2012;20(2-3):81-91
pubmed: 23193914
Autophagy. 2014 Jun;10(6):1120-36
pubmed: 24879157
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Toxicol Appl Pharmacol. 2015 Apr 1;284(1):33-41
pubmed: 25684043
J Pharm Pharmacol. 1989 Mar;41(3):160-3
pubmed: 2568441
Blood Cancer J. 2015 Apr 17;5:e307
pubmed: 25885427
Oncotarget. 2015 Nov 3;6(34):36354-69
pubmed: 26497553
PeerJ. 2015 Oct 06;3:e1314
pubmed: 26500823
Int J Cancer Res Mol Mech. 2015 Oct;1(3):null
pubmed: 26900603
Clin Cancer Res. 2016 Dec 15;22(24):6192-6203
pubmed: 27307592
Oncotarget. 2016 Aug 16;7(33):52928-52939
pubmed: 27447967
Oncotarget. 2017 Jan 3;8(1):248-267
pubmed: 27542249
Gynecol Oncol. 2017 Jul;146(1):187-195
pubmed: 28545688
Invest New Drugs. 2018 Jun;36(3):435-441
pubmed: 28971268
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Ann Trop Med Parasitol. 1988 Apr;82(2):107-12
pubmed: 3052330